COPENHAGEN, [November 22, 2024] – Cerebriu, a leader in AI-driven healthcare innovation, proudly announces the launch of its new brand identity, embodying the company’s renewed mission to ensure “Every Patient Diagnosed in Time.” This transformative vision reinforces Cerebriu’s commitment to accessibility, efficiency, and equity in medical imaging.
The rebranding introduces a modern logo, vibrant design, and focused messaging that reflect Cerebriu’s dedication to ensuring no patient is left behind in the diagnostic journey.
A Mission Grounded in Accessibility
“At Cerebriu, we believe that every patient deserves the right diagnosis at the right time,” said Robert Lauritzen, CEO of Cerebriu. “Our new brand represents our unwavering focus on bridging the gap between healthcare resources and patient needs through AI. Through strong partnerships and disruptive technology, we’re making a future where equitable healthcare is no longer aspirational—it’s achievable.”
“This rebrand isn’t just about a new look—it’s about aligning our identity with our mission to transform healthcare,” said Sonia Khelkhal, Head of Marketing at Cerebriu. “We’re positioning Cerebriu as a trusted partner not only to healthcare systems but also to patients worldwide. Our purpose resonates in every element of this rebrand innovation, inclusivity, and impact—reinforcing Cerebriu’s mission to democratize access to cutting-edge diagnostic tools. We’re creating a future where timely and accurate diagnosis is accessible to all, regardless of geographic or resource limitations.”
Driving Timely Diagnoses with AI
Central to Cerebriu’s mission is its flagship solution, Cerebriu Apollo, which integrates advanced AI to optimize Brain MRI radiology workflows. Key benefits include:
- Faster access to critical diagnoses through real-time detection of infarcts, hemorrhages, and tumors with Smart Priority.
- Personalized imaging protocols that adapt to individual patient needs, maximizing efficiency with Smart Protocol.
- Safe Reading Backlog ensuring cases with findings are prioritized for review without delay via Smart Reading.
These innovations directly support the promise of diagnosing every patient in time by reducing bottlenecks in diagnostic imaging and improving decision-making.
* Smart Priority, Smart Protocol, and Smart Reading are features of Cerebriu Apollo 2.1.2 (2-2031-5). Cerebriu Apollo is regulated as a medical device in the EU. This product conforms to Medical Device Directive 93/42/EEC and is covered by MDR 2017/745 Article 120. For investigational use only in the US.
